HRP20210734T1 - Koštani morfogenetski proteini - Google Patents
Koštani morfogenetski proteini Download PDFInfo
- Publication number
- HRP20210734T1 HRP20210734T1 HRP20210734TT HRP20210734T HRP20210734T1 HR P20210734 T1 HRP20210734 T1 HR P20210734T1 HR P20210734T T HRP20210734T T HR P20210734TT HR P20210734 T HRP20210734 T HR P20210734T HR P20210734 T1 HRP20210734 T1 HR P20210734T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid sequence
- seq
- bmp9
- variant
- Prior art date
Links
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 title 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 title 1
- 229940112869 bone morphogenetic protein Drugs 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 102000037280 Growth Differentiation Factor 2 Human genes 0.000 claims 11
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 7
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 230000005754 cellular signaling Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000007781 signaling event Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Polipeptid koji je varijanta koštanog morfogenetskog proteina 9 (BMP9) koja ima signalnu aktivnost endotelnih stanica i koji nema osteogenu aktivnost, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije odabrane iz skupine koju čine F362A, I375A, L379A, S402A, Y416A i Y418A.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije F362A.
3. Polipeptid prema patentnom zahtjevu 1, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije I375A.
4. Polipeptid prema patentnom zahtjevu 1, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije L379A.
5. Polipeptid prema patentnom zahtjevu 1, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije S402A.
6. Polipeptid prema patentnom zahtjevu 1, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije Y416A.
7. Polipeptid prema patentnom zahtjevu 1, naznačen time što se razlika između sekvence aminokiseline varijante BMP9 i sekvence aminokiseline SEQ ID NO: 4 sastoji od supstitucije Y418A.
8. Farmaceutski pripravak, naznačen time što sadrži polipeptid koji je varijanta koštanog morfogenetskog proteina 9 (BMP9) koja ima signalnu aktivnost endotelnih stanica i koji nema osteogenu aktivnost prema bilo kojem od patentnih zahtjeva 1-7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1412290.7A GB201412290D0 (en) | 2014-07-10 | 2014-07-10 | Novel use |
| EP19220066.5A EP3669886B1 (en) | 2014-07-10 | 2015-07-09 | Bone morphogenetic proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210734T1 true HRP20210734T1 (hr) | 2021-06-11 |
Family
ID=51453948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200418TT HRP20200418T1 (hr) | 2014-07-10 | 2020-03-13 | Terapeutska uporaba koštanih morfogenetičkih proteina |
| HRP20210734TT HRP20210734T1 (hr) | 2014-07-10 | 2021-05-11 | Koštani morfogenetski proteini |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200418TT HRP20200418T1 (hr) | 2014-07-10 | 2020-03-13 | Terapeutska uporaba koštanih morfogenetičkih proteina |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10336800B2 (hr) |
| EP (3) | EP3669886B1 (hr) |
| JP (1) | JP6737770B2 (hr) |
| KR (2) | KR20230049757A (hr) |
| CN (1) | CN106661094B (hr) |
| AU (1) | AU2015287397B2 (hr) |
| CA (1) | CA2954221C (hr) |
| CY (2) | CY1123011T1 (hr) |
| DK (2) | DK3669886T3 (hr) |
| ES (2) | ES2770073T5 (hr) |
| GB (1) | GB201412290D0 (hr) |
| HR (2) | HRP20200418T1 (hr) |
| HU (2) | HUE048924T2 (hr) |
| LT (2) | LT3166628T (hr) |
| MX (2) | MX2017000448A (hr) |
| PL (2) | PL3166628T5 (hr) |
| PT (2) | PT3166628T (hr) |
| RS (2) | RS61961B1 (hr) |
| RU (1) | RU2733318C2 (hr) |
| SI (2) | SI3166628T1 (hr) |
| WO (1) | WO2016005756A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201412290D0 (en) | 2014-07-10 | 2014-08-27 | Cambridge Entpr Ltd | Novel use |
| GB201603653D0 (en) * | 2016-03-02 | 2016-04-13 | Cambridge Entpr Ltd | Combination Therapy |
| CN110603049A (zh) * | 2017-02-06 | 2019-12-20 | 阿塞勒隆制药公司 | 用于治疗心力衰竭的组合物和方法 |
| AU2018358804A1 (en) * | 2017-11-02 | 2020-04-09 | Bayer Aktiengesellschaft | Bispecific antibodies binding ALK-1 and BMPR-2 |
| CN107760779B (zh) * | 2017-11-03 | 2020-10-16 | 中国医学科学院阜外医院 | 肺动脉高压相关的突变型bmp9基因及其应用 |
| CN111939245B (zh) * | 2019-05-16 | 2024-03-01 | 龚笑海 | 一种心脏治疗和保护的药物组合物 |
| WO2021113544A1 (en) * | 2019-12-03 | 2021-06-10 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| KR20220021207A (ko) * | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| WO2023012318A1 (en) * | 2021-08-05 | 2023-02-09 | Actelion Pharmaceuticals Ltd | Bmp9 variant polypeptides and uses thereof |
| CN114317604B (zh) * | 2022-03-04 | 2022-06-17 | 中国医学科学院阜外医院 | 一种自发性肺动脉高压模型及构建方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US171355A (en) * | 1875-12-21 | Improvement in driers | ||
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| WO1993000432A1 (en) * | 1991-06-25 | 1993-01-07 | Genetics Institute, Inc. | Bmp-9 compositions |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| WO1994026893A1 (en) | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-10 compositions |
| AU6787594A (en) | 1994-03-10 | 1995-09-25 | Human Genome Sciences, Inc. | Bone morphogenic protein-10 |
| AU2947395A (en) | 1995-06-06 | 1996-12-24 | Human Genome Sciences, Inc. | Bone morphogenic protein-10 |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| EP1571159A1 (en) | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| US7741284B2 (en) * | 2004-05-12 | 2010-06-22 | Acceleron Pharma Inc. | BMP10 propeptides and related methods |
| WO2006130022A1 (en) | 2005-05-30 | 2006-12-07 | Agresearch Limited | Modulation of ovulation by agonists and antagonists of bmprii |
| JP2009544325A (ja) | 2006-07-27 | 2009-12-17 | セントカー・インコーポレーテツド | Ｂｍｐ−７変異体組成物、方法および使用 |
| MX2009004718A (es) * | 2006-11-02 | 2009-06-19 | Acceleron Pharma Inc | Antagonistas de receptor de alk1 y ligando y sus usos. |
| EP2150560A1 (en) | 2007-06-01 | 2010-02-10 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| US8507501B2 (en) | 2008-03-13 | 2013-08-13 | The Brigham And Women's Hospital, Inc. | Inhibitors of the BMP signaling pathway |
| US8999928B2 (en) | 2009-04-01 | 2015-04-07 | Indiana University Research And Technology Corporation | Methods for treating diseases using a bone morphogenetic protein |
| WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
| JP6161541B2 (ja) * | 2011-02-03 | 2017-07-12 | ゾーマ テクノロジー リミテッド | 細菌中の機能的タンパク質発現を向上させるための方法および物質 |
| CN108178789B (zh) | 2011-04-20 | 2021-11-02 | 阿塞勒隆制药公司 | 内皮糖蛋白多肽及其用途 |
| US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| WO2014160203A2 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| GB201412290D0 (en) * | 2014-07-10 | 2014-08-27 | Cambridge Entpr Ltd | Novel use |
| PL3496739T3 (pl) * | 2016-07-15 | 2021-10-11 | Acceleron Pharma Inc. | Kompozycje zawierające polipeptydy actriia do stosowania w leczeniu nadciśnienia płucnego |
| CN107760779B (zh) | 2017-11-03 | 2020-10-16 | 中国医学科学院阜外医院 | 肺动脉高压相关的突变型bmp9基因及其应用 |
| KR20220021207A (ko) | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
-
2014
- 2014-07-10 GB GBGB1412290.7A patent/GB201412290D0/en not_active Ceased
-
2015
- 2015-07-09 EP EP19220066.5A patent/EP3669886B1/en active Active
- 2015-07-09 DK DK19220066.5T patent/DK3669886T3/da active
- 2015-07-09 LT LTEP15739658.1T patent/LT3166628T/lt unknown
- 2015-07-09 WO PCT/GB2015/051989 patent/WO2016005756A1/en active Application Filing
- 2015-07-09 MX MX2017000448A patent/MX2017000448A/es unknown
- 2015-07-09 SI SI201531119T patent/SI3166628T1/sl unknown
- 2015-07-09 RS RS20210631A patent/RS61961B1/sr unknown
- 2015-07-09 PL PL15739658.1T patent/PL3166628T5/pl unknown
- 2015-07-09 US US15/324,864 patent/US10336800B2/en active Active
- 2015-07-09 ES ES15739658T patent/ES2770073T5/es active Active
- 2015-07-09 RS RS20200199A patent/RS60181B1/sr unknown
- 2015-07-09 EP EP15739658.1A patent/EP3166628B2/en active Active
- 2015-07-09 JP JP2017500932A patent/JP6737770B2/ja active Active
- 2015-07-09 KR KR1020237010855A patent/KR20230049757A/ko not_active Application Discontinuation
- 2015-07-09 PT PT157396581T patent/PT3166628T/pt unknown
- 2015-07-09 DK DK15739658.1T patent/DK3166628T3/da active
- 2015-07-09 PT PT192200665T patent/PT3669886T/pt unknown
- 2015-07-09 PL PL19220066T patent/PL3669886T3/pl unknown
- 2015-07-09 LT LTEP19220066.5T patent/LT3669886T/lt unknown
- 2015-07-09 CA CA2954221A patent/CA2954221C/en active Active
- 2015-07-09 SI SI201531606T patent/SI3669886T1/sl unknown
- 2015-07-09 ES ES19220066T patent/ES2876124T3/es active Active
- 2015-07-09 CN CN201580036984.1A patent/CN106661094B/zh active Active
- 2015-07-09 RU RU2017102381A patent/RU2733318C2/ru active
- 2015-07-09 EP EP21158441.2A patent/EP3906936A1/en not_active Withdrawn
- 2015-07-09 AU AU2015287397A patent/AU2015287397B2/en active Active
- 2015-07-09 HU HUE15739658A patent/HUE048924T2/hu unknown
- 2015-07-09 KR KR1020177003531A patent/KR102519869B1/ko active IP Right Grant
- 2015-07-09 HU HUE19220066A patent/HUE054512T2/hu unknown
-
2017
- 2017-01-10 MX MX2020011333A patent/MX2020011333A/es unknown
- 2017-01-12 US US15/404,265 patent/US20170121383A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,006 patent/US11572396B2/en active Active
-
2020
- 2020-03-13 HR HRP20200418TT patent/HRP20200418T1/hr unknown
- 2020-03-19 CY CY20201100261T patent/CY1123011T1/el unknown
-
2021
- 2021-05-11 HR HRP20210734TT patent/HRP20210734T1/hr unknown
- 2021-05-14 CY CY20211100420T patent/CY1124143T1/el unknown
-
2023
- 2023-01-03 US US18/149,403 patent/US20240043485A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210734T1 (hr) | Koštani morfogenetski proteini | |
| EA201792651A1 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
| MA50746A (fr) | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive | |
| AU2019201173B2 (en) | Novel polypeptides | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| JP2017048194A5 (hr) | ||
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| HRP20211601T1 (hr) | Rekombinantni proteini bez fenilalanina (phe) za liječenje fenilketonurije | |
| JP2014132019A5 (hr) | ||
| JP2013172734A5 (hr) | ||
| MX2023001319A (es) | Polipeptidos condicionalmente activos. | |
| WO2015185758A3 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
| MY176200A (en) | Binding polypeptides having a mutated scaffold | |
| MX2016015594A (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina. | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| HRP20191511T1 (hr) | Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba | |
| MX360187B (es) | Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis. | |
| BR112018013246A2 (pt) | rótulo de peptídeo e proteína rotulada incluindo o mesmo | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| PH12017500742A1 (en) | Statherin peptides | |
| HK1259067A1 (zh) | 用牛免疫缺陷病毒gag蛋白的重組病毒樣顆粒 | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| PH12017550134A1 (en) | Il-37 variants |